• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Posaconazole
    3 Drugs classified under this active ingredient


    All the Active Ingredient Drugs

    Noxafil Concentrate for Solution for Infusion
    MSD
    RX
    partial basket chart
    Noxafil Concentrate for Solution for Infusion

    Triazole Derivatives. Posaconazole 300 mg/vial.
    VIAL.: 1 × 300 mg. Refract. invas. fung. infect. (IFI)/pts. with IFI intoler. to 1st line ther.: Load. dose of 300 mg×2/d. on the 1st day, then 300 mg ×1/d thereafter. Duration of ther. should be based on the severity of the underl. dis., recovery from immunosuppress., and clinic. response.
    Prophylaxis of invas. fung. infec.: Load. dose of 300 mg mg×2/d on the 1st day, then 300 mg mg ×1/d thereafter. Duration of ther. is based on recovery from neutropenia or immunosuppress. For pts. with AML or MDS, prophylaxis with Posaconazole should start several days before the anticip. onset of neutropenia and continue for 7 d. after the neutrophil count rises above 500 cells per mm³. See lit.
    Tmt. of the follow. fung. infec. in adult.: Invasive aspergillosis in pts. with dis. that is refract. to amphotericin B or itraconazole or in pts. who are intoler. of these med. products;
    Fusariosis in pts. with dis. that is refract. to amphotericin B or in pts. who are intolerant of amphotericin B;
    Chromoblastomycosis and mycetoma in pts. with dis. that is refractory to itraconazole or in pts. who are intoler. of itraconazole;
    Coccidioidomycosis in pts. with dis. that is refract. to amphotericin B, itraconazole or fluconazole or in pts. who are intoler. of these med. products.
    Zygomycosis, in pts. intoler. of, or with dis. that is refract. to, alternat. ther.
    Refractoriness is defined as progres. of infec. or fail. to improve after a min. of 7 d. of prior therapeutic doses of effective antifung. ther.
    Pts. receiving remiss.-induc. chemother. for acute myelogenous leuk. (AML) or myelodysplastic syndr. (MDS) expected to result in prolong. neutropenia and who are at high risk of developing invas. fungal infec.;
    Hematopoietic stem cell transplant (HSCT) recip. who are underg. high-dose immunosuppress. ther. for graft versus host dis. (GVHD) and who are at high risk of develop. invas. fungal infec.
    C/I: Hypersens. Co-admin. with ergot alkaloids. Co-admin. with the CYP3A4 substr. terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine since this may result in incr. plasma conc.  of these med. products, leading to QTc prolong. and rare occurrences of torsades de pointes. Co-admin. with the HMG-CoA reductase inhib. simvastatin, lovastatin and atorvastatin.

    Noxafil Oral Suspension
    MSD
    RX
    partial basket chart
    Noxafil Oral Suspension

    Triazole Derivatives. Posaconazole 40 mg/ml.
    BOTTLE: 105 ml. Refract. invas. fung. infect. (IFI)/pts. with IFI intoler. to 1st line ther.: 200 mg (5 mL) ×4/d. Alternatively, pts. who can tolerate food or a nutrit. supplem. may take 400 mg (10 mL) ×2/d during or immediat. follow. a meal or nutrit. supplem. Duration of ther. should be based on the sever. of the underl. dis., recovery from immunosuppress., and clinic. response.
    Oropharyng. candidiasis: Loading dose of 200 mg (5 mL)×1/d on the 1st day, then 100 mg (2.5 mL)×1/d for 13 d. Each dose should be adm. during or immed. after a meal, or a nutrit. supplem. in pts. who cannot tolerate food to enhance the oral absorp. and to ensure adequate exposure.
    Prophylaxis of invas. fungal infec.: 200 mg (5 mL) ×2/d. Each dose of Noxafil should be admin. during or immediate. after a meal, or a nutrit. supplem. in pts. who cannot tolerate food to enhance the oral absorp. and to ensure adequate exposure. The duration of ther. is based on recovery from neutropen. or immunosuppress. For pts. with acute myelogenous leukemia or myelodysplastic syndr., prophylaxis with Noxafil should start several days before the anticip. onset of neutropenia and continue for 7 d after the neutrophil count rises above 500 cells per mm³.
    Tmt. of the follow. fung. infec. in adult.: Invasive aspergillosis in pts. with dis. that is refract. to amphotericin B or itraconazole or in pts. who are intoler. of these med. products;
    Fusariosis in pts. with dis. that is refract. to amphotericin B or in pts. who are intolerant of amphotericin B;
    Chromoblastomycosis and mycetoma in pts. with dis. that is refractory to itraconazole or in pts. who are intoler. of itraconazole;
    Coccidioidomycosis in pts. with dis. that is refract. to amphotericin B, itraconazole or fluconazole or in pts. who are intoler. of these med. products.
    Zygomycosis, in pts. intoler. of, or with dis. that is refract. to, alternat. ther.
    Refractoriness is defined as progres. of infec. or fail. to improve after a min. of 7 d. of prior therapeutic doses of effective antifung. ther.
    Pts. receiving remiss.-induc. chemother. for acute myelogenous leuk. (AML) or myelodysplastic syndr. (MDS) expected to result in prolong. neutropenia and who are at high risk of developing invas. fungal infec.;
    Hematopoietic stem cell transplant (HSCT) recip. who are underg. high-dose immunosuppress. ther. for graft versus host dis. (GVHD) and who are at high risk of develop. invas. fungal infec.
    C/I: Hypersens. Co-admin. with ergot alkaloids. Co-admin. with the CYP3A4 substr. terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine since this may result in incr. plasma conc.  of these med. products, leading to QTc prolong. and rare occurrences of torsades de pointes. Co-admin. with the HMG-CoA reductase inhib. simvastatin, lovastatin and atorvastatin.

    Noxafil Tablets
    MSD
    RX
    partial basket chart
    Noxafil Tablets

    Triazole Derivatives. Posaconazole 100 mg.
    GASTRO-RESIS. TABS.:24. Refract. invas. fung. infect. (IFI)/pts. with IFI intoler. to 1st line ther.: Load. dose of 300 mg (three 100 mg tabs.) ×2/d on the 1st day, then 300 mg (three 100 mg tabs.) ×1/d thereafter.
    Each dose may be taken without regard to food intake. Duration of ther. should be based on the severity of the underl. dis., recovery from immunosuppress., and clinic. response.
    Prophylax. of invas. fung. infec.: Load. dose of 300 mg (three 100 mg tabs.) ×2/d on the 1st day, then 300 mg (three 100 mg tabs.) ×1/d thereafter.
    Each dose may be taken without regard to food intake. Duration of ther. is based on recovery from neutrop. or immunosuppress. For pts. with acute myelogenous leukem. or myelodysplas. syndr., prophylax. with posaconazole should start several days before the anticip. onset of neutropen. and cont. for 7 d. after the neutrophil count rises above 500 cells per mm3. See lit.
    Tmt. of the follow. fung. infec. in adult.
    Invas. aspergillos. in pts. with dis. that is refract. to amphotericin B or itraconazole or in pts. who are intoler. of these med. products;
    Fusariosis in pts. with dis. that is refract. to amphotericin B or in pts. who are intoler. of amphotericin B;
    Chromoblastomycosis & mycetoma in pts. with dis. that is refract. to itraconazole or in pts. who are intoler. of itraconazole;
    Coccidioidomycosis in pts. with dis. that is refract. to amphotericin B, itraconazole or fluconazole or in pts.who are intoler. of these med. products.
    Zygomycosis in pts. intoler. of or with dis. that is refract. to alternat. ther.
    Refractoriness is defined as progres. of infec. or failure to improve after a min. of 7 d. of prior therap. doses of effective antifung. ther.
    Prophylax. of invas. fung. infect. in the follow.: Pts. receiv. remiss. –induct. chemother. for acute myelogenous leukemia (AML) or myelodysplastic syndr. (MDS) expected to result in prolong. neutropen. and who are at high risk of develop. invas. fung. infect.;
    Hematopoiet. stem cell transplant (HSCT) recipients who are underg. high-dose immunosuppress. ther. for graft versus host dis. and who are at high risk of develop. invas. fung. infect.
    C/I: Hypersens. Co-admin. with ergot alkaloid. Co-admin. with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine since this may result in incr. plasma conc. of these med. products, leading to QTc prolong. and rare occurrences of torsades de pointes.
    Co-admin. with the HMG-CoA reductase inhib. simvastatin, lovastatin and atorvastatin.

    CLOSE